• pg电子官网

    EN
    EN
    EN

    • 业务咨询

      中国：

      Email: marketing@shtongxi.com.cn

      业务咨询专线：400-780-8018

      （仅限服务咨询，其他事宜请拨打川沙总部电话）

      川沙总部电话: +86 (21) 5859-1500

      海外：

      +1(781)535-1428(U.S.)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在线留言×
    点击切换
    Customer Center
    客户中心

    合成具有体内抗肿瘤活性的强效PD-L1抑制剂，并进行生物学评价和机制研究。PK研究通过pg电子官网进行

    2023-07-05
    |
    访问量：

    PD-1 and PD-L1 have been very successful for the treatment of various tumors, including NSCLC, urothelial cancer, melanoma, head and neck squamous cell cancer, and lymphoma. Researchers identified compound L7 as a potent PD-L1 inhibitor that blocked PD-1/PD-L1 interaction. Pharmacokinetic (PK) studies demonstrated that L7 was orally bioavailable. PK studies were conducted by Medicilon.

    51.png

    Reference:

    Liu Liu, et al. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[ c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. J Med Chem. 2021 Jun 24;64(12):8391-8409. doi: 10.1021/acs.jmedchem.1c00392. 

    相关新闻
    ×
    搜索验证
    点击切换
    友情链接: